Malin has returned to support an oversubscribed series B round, led by Longitude Capital.
Poseida Therapeutics, a US-based startup developing drugs based on gene engineering, raised $30.5m in an oversubscribed series B round on Tuesday from investors including life sciences company Malin.
The round was led by Longitude Capital and also featured Vivo Capital and Tavistock Group. David Hirsch, managing director at Longitude Capital, has joined Poseida’s board of directors.
Founded in 2014, Poseida Therapeutics is developing immunotherapies and gene therapies using gene engineering technologies.
The company currently has one therapy, P-BCMA-101, in a…
